|
R3HDM1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.73583369900143E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.97929467155222E-11 |
| Normal-vs-Stage2 |
1.67492999999519E-05 |
| Normal-vs-Stage3 |
2.70339306496226E-13 |
| Normal-vs-Stage4 |
2.19213536212237E-12 |
| Stage1-vs-Stage2 |
3.053600E-01 |
| Stage1-vs-Stage3 |
1.680280E-02 |
| Stage1-vs-Stage4 |
1.728450E-02 |
| Stage2-vs-Stage3 |
1.241810E-02 |
| Stage2-vs-Stage4 |
9.559100E-03 |
| Stage3-vs-Stage4 |
8.551400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.99280649946377E-15 |
| Normal-vs-AfricanAmerican |
4.10430000000739E-05 |
| Normal-vs-Asian |
6.25160000433667E-08 |
| Caucasian-vs-AfricanAmerican |
3.583600E-01 |
| Caucasian-vs-Asian |
4.205200E-01 |
| AfricanAmerican-vs-Asian |
7.829000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.16849996345536E-09 |
| Normal-vs-Female |
1.68287606072681E-12 |
| Male-vs-Female |
6.298200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.16590112301196E-11 |
| Normal-vs-Age(41-60Yrs) |
1.88293824976427E-13 |
| Normal-vs-Age(61-80Yrs) |
1.03300001885742E-09 |
| Normal-vs-Age(81-100Yrs) |
1.481950E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.426600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.830200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.697800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.289600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.377800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.766600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.256000E-02 |
| Classical-VS-Follicular |
4.032200E-02 |
| Classical-VS-Other |
3.199000E-01 |
| Classical-VS-Normal |
1.78701498043665E-12 |
| Tall-VS-Follicular |
3.115500E-03 |
| Tall-VS-Other |
8.474400E-01 |
| Tall-VS-Normal |
6.72979449944933E-11 |
| Follicular-VS-Other |
1.440750E-01 |
| Follicular-VS-Normal |
4.06099999999965E-05 |
| Other-VS-Normal |
9.83030000000218E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.44699815965532E-11 |
| Normal-vs-N1 |
1.16184839527023E-12 |
| N0-vs-N1 |
4.103700E-02 |
|
|
